Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which pill works better for acne? new study compares hormone therapy vs antibiotic

NCT ID NCT04582383

Symptom relief Sponsor: University of Pennsylvania Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 26, 2026 · Updated 2 times

Summary

This study compares two common acne pills for women: spironolactone (a hormone blocker) and doxycycline (an antibiotic). About 350 women aged 16-40 with moderate to severe acne will take one of the two medicines for several weeks. Researchers will count how many pimples clear up and check skin improvement to see which treatment works better.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 350 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2022

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

16 to 40 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female sex assigned at birth * Age 16-40 years old * Acne defined as at least 10 inflammatory papules or pustules and an Investigator's Global Assessment (IGA) score of at least 2 as measured by the Comprehensive Acne Severity Scale * Not currently pregnant or planning to become pregnant Exclusion Criteria: * Pregnancy * Heart disease * Renal disease * Liver disease * Orthostatic hypotension * Addison's disease * History of hyperkalemia * Allergy to tetracycline-class antibiotic * Allergy to spironolactone * Concomitant use of medications known to interact with spironolactone or doxycycline or that may increase the risk for hyperkalemia, including angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, eplerenone, nonsteroidal anti-inflammatory drugs, and digoxin. * Treatment with spironolactone, an oral antibiotic, laser, photodynamic therapy, or chemical peel within the past 4 weeks * Treatment with isotretinoin within the past 3 months * Sebacia laser treatment within the past 12 months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acne are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acne Acne Vulgaris

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acne

Contacts and locations

Locations

  • Arlington Research Center

    Arlington, Texas, 76011, United States

  • Brigham and Women's Hospital

    Boston, Massachusetts, 02115, United States

  • CCS Texas

    Houston, Texas, 77004, United States

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania, 19104, United States

  • Cura Clinical Research

    Sherman Oaks, California, 92866, United States

  • Cyn3rgy Research

    Gresham, Oregon, 97030, United States

  • Dawes Fretzin Clinical Research Group

    Indianapolis, Indiana, 46250, United States

  • Dermatologists of Central States

    Cincinnati, Ohio, 45242, United States

  • Johnson Dermatology

    Fort Smith, Arkansas, 72916, United States

  • New Horizon Research Center

    Miami, Florida, 33165, United States

  • New York University

    New York, New York, 10016, United States

  • North Texas Center for Clinical Research

    Frisco, Texas, 75034, United States

  • Northwell Health

    North New Hyde Park, New York, 11042, United States

  • Ohio State University Medical Center

    Columbus, Ohio, 43215, United States

  • Oregon Health and Science University

    Portland, Oregon, 97239, United States

  • University of California San Francisco

    San Francisco, California, 94115, United States

  • University of Miami

    Miami, Florida, 33136, United States

  • University of Pennsylvania

    Philadelphia, Pennsylvania, 45209, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.